MultiOmic discovers and develops precision medicines for metabolic syndrome-derived diseases. The company uses deep longitudinal patient datasets, AI-enabled data science capabilities, and experimental biology expertise to identify patient subpopulations with distinct molecular-level disease drivers.

MultiOmic

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). 

Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

Verve Ventures

Ada Ventures

MMC Ventures

Hoxton Ventures

Selvedge Venture

OpenNano Pte. Ltd.

Pareto Holdings

Fifty Years

Formic Ventures

HOF Capital

Edward Lando

Jon Oringer

Nadav Ben-Chanoch

Multiomic Health

MultiOmic Health have some exciting news to share! Today, we are thrilled to announce our over-subscribed $6.2 million Seed Extension round, led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures.

This financing will enable us to take the next step in our journey to demonstrate proof-of-concept for our MOHSAIC platform in diabetic kidney disease, a condition with huge unmet medical need that now accounts for an estimated $300 billion annually in global healthcare costs.

We’d like to welcome all our new investors, and thank our existing investors for their ongoing support. Also, a huge shout out to the entire MultiOmic team, without whom none of this would have been possible.

Stay tuned for more updates on our progress and our continued commitment to advancing precision medicine for metabolic syndrome-related conditions.
#fundraising #investment #lifesciences #biotechnology #drugdiscovery #bioinformatics

We're thrilled to announce our participation at #BioEquityEurope 2024! 🚀 

🗓️ Save the date for May 14th at 14:20 CEST, where you can find us in Room 4+5 at the Kursaal Elkargunea Center, San Sebastián, Spain.

🌟 Robert Thong, our CEO at Multiomic Health, will be presenting on our innovative approach to tackle cardiorenal complications. Join us for insights into how we aim to transform the landscape of metabolic syndrome through precision medicine. 

🤝 We'd love to connect with you! Schedule a meeting with Robert or our COO, Celia Antonio Schell, and be sure to connect with us via the Bio€quity online partnering platform.

See you there!
#BioEquityEurope #PrecisionMedicine #MetabolicSyndrome #MultiOmicHealth

🌟 Exciting News Alert! 🌟

We're proud to announce our partnership with the Centre for Public Health at Queen's University Belfast (QUB) to revolutionise treatment for patients with diabetic kidney disease (DKD).

With the support of Innovate UK's Advancing Precision Medicine programme, we're leveraging insights from two world-class studies conducted by researchers at QUB and the Folkhälsan Research Centre.

Our goal is clear: to deliver more accurate diagnosis and treatment stratification for both type 1 and type 2 diabetes patients through the development of data-driven diagnostic tools.

Stay tuned for updates!

#MultiOmicHealth #QueensUniversityBelfast #Folkhälsan #NICOLA #FinnDiane #DiabeticKidneyDisease #Innovation #Collaboration

Andrew Parton Heather Jackson Rebecca Cripps Gareth McKay McKnight Amy Jayne, Prof Claire Hill, DPhil Laura Smyth Per-Henrik Groop Niina Sandholm Stefan Mutter

https://lnkd.in/dP8ivQhh

I'll be presenting Multiomic Health at the #BioEquityEurope conference week. Look forward to catching up with old friends and meeting new ones.

Proud to be selected as one of the top startups to pitch at Sifted tomorrow! 
Registration link to attend here: https://lnkd.in/euvP_jY4.

Domain Not Resolving

Mobile Non Scaleable Content

Chief of Staff & Finance Manager

Esra Berkol

Manuel Mayr

Angeli Möller

Celia Antonio Schell

Head of Clinical Operations

Alasdair Thong

Co-Founder

Ariella Cohain

Head of Computational Biology

Andrew Parton

Lead Data Scientist

Chief of Staff & Marketing Director

Robert Thong

Co-Founder, Chairman & Chief Executive Officer

Slaven Stekovic

COO & President

Europe Biotechnology Companies (Top 10K)

Europe Seed Stage Companies With Fewer Than 100 Employees (Top 10K)

United Kingdom Life Science Companies

Therapeutics Companies with Seed Funding

MultiOmic Health is an AI-enabled drug discovery (AIDD) start-up focused on metabolic syndrome-related diseases. It partners with carefully selected healthcare providers to source and analyse de-identified patient data and bio-samples. MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments to originate novel precision therapeutic concepts that MultiOmic commercialises via partnerships with established biopharma companies.

Seed Round - MultiOmic Health

Pre Seed Round - MultiOmic Health

Computer and Software Services and Scientific Services

London

England

United Kingdom

Europe

MultiOmic Health

U.S. Multiomics Market Size to Reach USD 4.88 Billion by 2033

Multiomics Market Size, Share & Trends Analysis Report 2024-2030: Decreasing Costs of Omics Technologies, Public ...

The Global Multiomics Market Reach Valued At $7.65 Billion by 2031 As Revealed In New Report

MultiOmic Health and Queen's University Belfast join forces to transform diabetic kidney disease dia

11 drug discovery startups to watch, according to VCs

UK’s MultiOmic Health secures €5.7M for its AI-enabled precision drug discovery platform

MultiOmic Health Closes $6.2M Funding Round

United States

North America

Czech Republic

Germany

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Jul 29, 2024 10:58 PM	6b4fd844
public peers	general	Jul 29, 2024 3:49 AM	d2cd58f8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 29, 2024 8:47 AM	cbb1639a
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	31d10c61
crunchbase profile	general	Nov 4, 2024 11:32 AM	e395650d
li profile	general	Jul 29, 2024 3:49 AM	25f17b00
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	1acb0c0c
peers	general	Jul 29, 2024 3:49 AM	cf2afa5b
news basic	general	Jul 29, 2024 3:49 AM	55f2f5da
bundesanzeiger	filings
financials download nd	financials
private financials	financials

HEALTH:MULTIOMIC

MultiOmic